statements regarding financial
information for future periods, contain forward-looking statements, and
such statements are made pursuant to the safe harbour provisions of the
Private Securities Litigation Reform Act of 1995. These statements involve
risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements.
Several factors, including timing of FDA approvals, changes in customer
forecasts, our failure to meet customers' purchase order and quality
requirements, supply shortages, production delays, changes in the markets
for customers' products, introduction timing and acceptance of our new
products scheduled for fiscal year 2008, and introduction of competitive
products and other factors beyond our control, could result in a materially
different revenue outcome and/or in our failure to achieve the revenue
levels we expect for fiscal 2008. A more complete description of these and
other risks that could cause actual events to differ from the outcomes
predicted by our forward looking statements is set forth under the caption
"Risk Factors" in our annual report on Form 10-K and other reports we file
with the Securities and Exchange Commission from time to time, and you
should consider each of those factors when evaluating the forward looking
statements.
ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Vantus, Inc.
Web site: http://www.vantuslabs.com
Contact: Investor Relations
+1-916-858-5107,
or ir@thermogenesis.com
'/>"/>SOURCE ThermoGenesis Corp. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets2.
ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year3.
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 20084.
ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 20075.
ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 20076.
ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results7.
ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 20078.
Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration9.
Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity10.
Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.11.
AMDLs Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment